Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

CASI Pharmaceuticals Q2 EPS $(0.52) Beats $(0.63) Estimate, Sales $3.98M Miss $4.43M Estimate

Author: Benzinga Newsdesk | August 16, 2024 08:02am
CASI Pharmaceuticals (NASDAQ:CASI) reported quarterly losses of $(0.52) per share which beat the analyst consensus estimate of $(0.63) by 17.46 percent. This is a 32.47 percent increase over losses of $(0.77) per share from the same period last year. The company reported quarterly sales of $3.98 million which missed the analyst consensus estimate of $4.43 million by 10.18 percent. This is a 59.48 percent decrease over sales of $9.82 million the same period last year.

Posted In: CASI


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist